Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
cyclophosphamide (cytoxan) (1 trial)
docetaxel (taxotere) (1 trial)
doxorubicin (Doxil) (1 trial)
selumetinib (Koselugo) (1 trial)
Breast Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Trials (1 total)
Trial APIs (4 total)